QUOIN PHARMACEUTICALS

Corporate Overview: Non-Confidential

December 2024

quoinpharma.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

QUOIN PHARMACEUTICALS

This presentation contains forward-looking statements, which are based on our management's current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us.

In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words. Any statements in this presentation about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: our product pipeline; anticipated regulatory filings; regulatory approvals and the timing thereof; plans for clinical trials and studies and the timing thereof; plans to develop and commercialize products and the highly attractive commercial opportunity.

These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such risks, uncertainties and other factors relate to, among other things: our ability to generate favorable pre-clinical and clinical trial results; our ability to identify and develop potential product candidates; additional costs or delays associated with unsuccessful clinical trials; the inability to predict the timing of revenue from sales of a future product; the extensive regulatory requirements and future developmental and regulatory challenges we will still face even if we obtain approval for a product candidate; our ability to obtain or maintain orphan drug designation or data exclusivity for our product candidates; our ability to obtain Orphan Disease and Rare Pediatric Disease designations for our product candidates; our manufacturing processes may not be validated and our methodology may not be accepted by the scientific community; and the ability to conduct clinical trials, because of difficulties enrolling patients or other reasons.

You should refer to "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 14, 2024, as updated by our subsequent filings with the SEC, for a discussion of these and other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We qualify all of our forward-looking statements by these cautionary statements.

This presentation may contain market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this presentation is generally reliable, such information is inherently imprecise.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this presentation, even if new information becomes available in the future.

Investment Highlights

QUOIN PHARMACEUTICALS

Experienced **Management Team** with proven track record of success

Netherton Syndrome clinical trials underway under **open IND.** Sites in US, EU, Middle East

Establishing **own sales infrastructure** for both US and EU markets

Focused **Rare and Orphan Disease** product pipeline

Targeting Netherton Syndrome US,EU,ROW **Approval in 2026**

Nine Ex-US and EU **Partnerships** in place covering **61 countries**

Rare Pediatric Designation opportunity for lead products

Peeling Skin Clinical Program Initiated

Quoin Products will effectively be **commercialized Globally**

Product Pipeline

QUOIN PHARMACEUTICALS

Product Candidate	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Approval
QRX003	• Netherton Syndrome*					
	• Peeling Skin Syndrome**					
	• SAM Syndrome					
	• Palmoplantar Keratoderma***					
QRX008	• Scleroderma					
QRX007	• Netherton Syndrome					
QRX004	• Epidermolysis Bullosa					



*3 Clinical studies underway
**Clinical trial initiated
***Clinical testing to commence Q12025

Netherton Syndrome (NS)

NS is caused by a mutation of the SPINK5 (serine protease inhibitor, Kazal Type 5) gene





Netherton Syndrome

QUOIN PHARMACEUTICALS

3000 – 4000[1]

Patients in US, similar number in Europe

1 in 200,000[2]

Newborns affected

Daily Treatment

for the remainder of the patient's life

- Devastating genetic disease
- Form of Ichthyosis
- Patients suffer from multiple severe issues:
- Infections, allergies, asthma, skin cancer,
- pruritis, warts
- Can be hospitalized on multiple occasions annually
- Environmental toxins, allergens and other micro-organisms can pass through virtually unhindered
- Patients often need to coat their whole body with a moisturizer 5-6 times daily

(1) https://rarediseases.info.nih.gov/diseases/7182/netherton-syndrome
(2) https://pmc.ncbi.nlm.nih.gov/articles/PMC10890808/

QRX003 Targets the Vicious Circle of Skin Inflammation and Barrier Disruption

QUOIN PHARMACEUTICALS

Broad Spectrum Serine Protease Inhibition Plus Anti-inflammatory Activity

Serine Protease Inhibitor/ Anti-inflammatory

- Targets the KLK5, KLK7 and KLK14 kallikreins that are responsible for excess skin shedding
- Potent anti-inflammatory
- Adequately penetrates the skin but is not absorbed systemically

Invisicare Delivery Technology

- Immediate protection against TEWL and environmental agents
- Moisturizes and protects skin
- Patented polymer delivery system
- Topical lotion

QRX003

Active ingredient replaces missing LEKTI protein, enabling the skin barrier to be repaired. Moisturizes and protects skin.

Clinical and Regulatory Pathway

QUOIN PHARMACEUTICALS

Clear Clinical Path Forward based on FDA Feedback

- Approximately 20 Subjects may be sufficient for Approval
- QRX003 Qualifies for One or More Expedited Approval Pathways
- FDA Recommended Assessing 5 Different Endpoints, Including Composite Endpoints of Investigator and Patient Data
- Lowered Requirements for Achieving a Successful Clinical Outcome

Positive Scientific Advice Received from EMA

Three Clinical Trials Underway in NS Patients

Targeting filing in US, EU, ROW in late 2025/early 2026



Three NS Clinical Trials Underway

QUOIN PHARMACEUTICALS

Placebo Controlled

Subjects must wash out of Systemic Therapy

QRX003 vs. Placebo

30 subjects

Age 14 and above

Test material applied 2x/day to pre-defined areas

Open Label

Subjects must be on Systemic biologics for the duration of the study

All subjects receive test material

20 subjects

Age 14 and above

Test material applied 2x/day to pre-defined areas

Pediatric

First Subject in Ireland dosed

Up to 3 Subjects in Spain planned to be dosed Q1’25

Up to 6 subjects in UK planned to be dosed Q2’25

All subjects receive test material

Dosing is 2x/day to pre-defined areas

5 Sites Opened in US

International Sites now being opened in Saudi Arabia, UK, Western Europe, and Eastern Europe

Initial Open Label Part A Data On Completion of 12 Weeks Dosing

- Pruritis:
  - 5 subjects reported absence of or negligible pruritis
  - 1 subject unchanged
- IGA/M-IASI
  - 3 subjects demonstrated improvement on completion
  - 3 subjects showed improvement during study
- PASA:
  - Positive feedback across a number of metrics including: ease of use, time to start working, overall satisfaction, lack of side effects
  - Above data is from once-daily dosing. Currently subjects are being dosed twice daily

*All data reported is change from baseline

Investigator Pediatric Study

- First Subject in Ireland being dosed
- Up to 3 Subjects in Spain planned to be dosed Q1’25
- Up to 6 subjects in UK planned to be dosed Q2’25

Commercial Initiatives

- Launching ‘Netherton Now’ awareness campaign
- Events, media, social media, conferences to increase awareness within general population, treating physicians, and the patient community
- Working with commercial consultants to develop pricing strategy based on actual claims and payer data
- Engaging lobbying firm to interact with local and national lawmakers and establish key relationships

Highly Attractive Commercial Opportunity

QUOIN PHARMACEUTICALS

- QRX003 is a **'Whole Body, Whole Life'** Product
- **Small, compact sales force** will effectively detail QRX003 in both US and EU
- Estimated **6,000-8,000 patients** in US and EU. Approximately, 30,000 globally
- **Upside sales potential** outside of US and EU. Nine partnerships established covering 61 countries. Potential to participate in Early Access programs ahead of regulatory approval

QRX003 For Additional Rare Skin Disorders

QUOIN PHARMACEUTICALS



Peeling Skin Syndrome

- <1/1000000
- Caused by mutations in the TGM5 gene
- Causes peeling of the top layer of skin
- Most apparent on the hands and feet



SAM Syndrome

Severe dermatitis, multiple allergies, and metabolic wasting (SAM)

- Caused by mutations in the desmoglein 1 gene (DSG1)



Palmoplantar Keratoderma

- 4.4 cases per 100,000
- Causes Thickening of the skin on the hands and feet
- Can be acquired or inherited

Currently no approved treatments for these diseases.
Peeling Skin Study Started in New Zealand
Clinical testing in PPK to commence in 2025.

QRX008 for Scleroderma



- In-licensed from Queensland University of technology (QUT), Australia
- No currently approved treatments for scleroderma, a rare and sometimes fatal autoimmune disease
- Caused by over production of collagen which results in hardening of the skin and connective tissue
- Focus is on investigating small molecule inhibition of the VCAM-1: VL-4 interaction
- There is an established genetic and clinical link for VCAM1 in scleroderma and the pivotal role VL-4 plays in controlling immune cell migration into inflamed tissue
- Therefore, the VCAM-1:VL-4 interaction is an attractive target for therapeutic intervention in scleroderma.
- Proof of concept has already been established in a mouse model
- Additional studies underway to select a candidate for clinical testing.

QRX007 for Netherton Syndrome



- **In-licensed from QUT, Australia**
  - Active is a dual domain serine protease inhibitor with proven anti inflammatory-activity
  - Already in use as a biopharmaceutical (Ulinastatin, Miraclid) for treatment of acute and chronic pancreatitis, Sepsis and toxic epidermal necrolysis
  - Active has achieved low nanomolar inhibitory potencies against the KLK7 and KLK5 kallikreins
  - Drug is a human protein and so is highly unlikely to provoke an immune response
- **Pre-clinical program underway at QUT**
- **Quoin has global rights in return for a mid-single digit royalty on future sales**

Strong Management Team with Proven Track Record of Success

QUOIN PHARMACEUTICALS

Name	Position	Experience
Dr. Michael Myers	CEO	elan, FUISZ technologies, West By your side for a healthier world, innocoll Engineering Better Medicines
Denise Carter	COO	FUISZ technologies, CardinalHealth, EURAND, West By your side for a healthier world, innocoll Engineering Better Medicines
Gordon Dunn	CFO	NEWSMITH, innocoll Engineering Better Medicines, Qured

Seasoned executives with over 90 years experience developing products based on drug delivery technologies

Proven track record transitioning companies to key inflection points, including mergers, reverse mergers acquisitions and IPOs

Raised over $250M in private and public markets.

Deep commercialization experience in US and Europe

QUOIN
PHARMACEUTICALS

THANK YOU

quoinpharma.com